Regarding the use of ICIs in combination with chemotherapy in HER2-mutated patients in a first-line setting, the observed outcomes are similar to those of the non-selective NSCLC cohort in the KEYNOTE-189 trial with an ORR, median PFS and a one-year OS of 52%, 6 months, and 88%, respectively [24,25]. Here, ERBB2 is linked to non-small cell lung carcinoma.